Relativity between lipoprotein(a) or apolipoprotein B and coronary heart disease in hemodialysis patients
ZHANG Peng1, LUAN Chunyu2, JIANG Shan3
(1. Department of Nephrology, 2. Department of Pulmonary and Critical Care Medicine, 3. Department of Cardiology, the Second Affiliated Hospital of Shandong First Medical University, Taian Shandong 271000, China)
Abstract：Objective To investigate the relationship between lipoprotein(a) or apolipoprotein B and coronary heart disease(CHD) in hemodialysis patients. Methods Clinical baseline data of 151 hemodialysis patients were collected, and the levels of lipoprotein(a) and apolipoprotein B were measured by enzymelinked immunosorbent assay (ELISA). According to medical history and coronary angiography results, these patients were divided into two groups: CHD group (39 cases) and non-CHD group (112 cases). Multivariate Logistic regression analysis was utilized to screen out the independent risk factors of CHD in hemodialysis patients. ResultsThe lipoprotein(a) level in the CHD group was higher than that in the nonCHD group, without statistically significant difference [(266.21±308.30) mg/L vs. (221.42±304.30) mg/L, P=0.10]. Age (OR=1.144, 95%CI 1.053-1.239, P<0.01), male (OR=2.092, 95%CI 1.340-3.270, P<0.01), diabetes (OR=1.678, 95%CI 1.102-2.572, P<0.05) and apolipoprotein B level (OR=1.191, 95%CI 1.081-1.322, P<0.01）were all independent risk factors of CHD in hemodialysis patients. Conclusion Besides classic risk factors of CHD such as age, male and diabetes, apolipoprotein B also contributes to the high prevalence of CHD in hemodialysis patients.
